ACAD — Acadia Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $4.34bn
- $3.48bn
- $1.07bn
Brief: Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Acadia Pharmaceuticals Announces Exclusive License Agreement With Saniona For SAN711
Brief: Acadia Pharmaceuticals Inc - On Nov 18, Co Involuntarily Terminates COO Brendan Teehan
Acadia Pharmaceuticals Inc Reports Results For The Quarter Ended In September 30: Earnings Summary
Brief: Acadia Pharmaceuticals Q3 EPS USD 0.2 Vs. IBES Estimate USD 0.14
Neuren Pharmaceuticals tops benchmark after US partner sells FDA review voucher
Brief: Acadia Pharmaceuticals Announces Health Canada Approval Of DAYBUE (Trofinetide) For The Treatment Of Rett Syndrome
Acadia Pharmaceuticals appoints Catherine Owen Adams CEO, shares fall
Brief: Catherine Owen Adams Succeeds Steve Davis As CEO Of Acadia Pharmaceuticals
Brief: Axcelead Drug Discovery Partners Enters Into Master Service Agreement For Drug Discovery Projects With Acadia Pharmaceuticals
U.S. RESEARCH ROUNDUP-Duolingo, Nova, Universal Health Services
U.S. RESEARCH ROUNDUP-Amgen, Atkore, Moneylion
Acadia Pharmaceuticals Inc Reports Results For The Quarter Ended In June: Earnings Summary
Brief: Acadia Pharmaceuticals Q2 EPS USD 0.2 Vs. IBES Estimate USD 0.18
Acadia Pharmaceuticals Inc Expected To Post Earnings Of 18 Cents A Share: Earnings Preview
Brief: ACADIA Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule
U.S. RESEARCH ROUNDUP- Corpay, Epam Systems, MKS Instruments
U.S. RESEARCH ROUNDUP- Crescent Energy, Rockwell Automation, Transdigm Group
Australia's Neuren Pharmaceuticals tumbles on weak sales from US drug licensee